CoChat

An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder

Open access

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: Methylphenidate is the first-line pharmacological treatment of attention-deficit/hyperactivity disorder (ADHD). Although methylphenidate has a well-established evidence base for treating ADHD, its long-term benefits are unclear. Areas covered: Physical adverse effects, psychiatric adverse events and brain development Expert opinion: Some physical adverse events have been described (e.g. sleep disturbances, growth reduction, loss of appetite), although most are of transient nature. Psychiatric adverse events seem more related to the diagnosis ADHD itself, and not stimulant treatment. Concluding, short-to-mid-term use (i.e., up to 2 years) stimulants are relatively safe, but much less is known about longer-term efficacy and safety of these drugs.

Overview

Integrity signals

Registry

Crossref · 10.1080/14740338.2017.1301928

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 124 references

Research works printed but not linked: 5

  1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders [DSM-IV-TR]. Washington (DC): American Psychiatric Association; 2000.
  2. Storebo OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015 Nov 25;(11):Cd009885. Epub 2015 Nov 26.
  3. Johnson MR. Increased cardiovascular risk associated with methylphenidate use in children and adolescents with ADHD? Examine the evidence. BMJ. 2016;353:i2550. [letter to the editor]
  4. 10.1001/jama.1976.03260390035024 · DOI
  5. 10.1176/appi.ajp.163.7.1149 · doi:10.1176/appi.ajp.163.7.1149 · Paper page

Cited by

See all 57

Metadata

Authors
Groenman, A. P., Schweren, L. J. S., Dietrich, A., & Hoekstra, P. J.
Affiliations
  • University Medical Center Groningen (NL)
  • University of Cambridge (GB)
Corresponding author
Groenman, Annabeth P.
Venue
Expert Opinion on Drug Safety
Published
2017-03-09
Volume
16
Issue
4
Pages
455-464
ISSN
  • 1474-0338 (ISSN-L)
  • 1744-764X
OpenAlex
W2592348399
Cited by
46
References
123
Citations by year
2026: 1 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 10 · 2020: 5 · 2019: 8 · 2018: 7 · 2017: 3
FWCI
0.95
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • Expert Opinion on Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Social Sciences › Arts and Humanities › Philosophy › Neuroethics, Human Enhancement, Biomedical Innovations
Keywords
attention deficit hyperactivity disorder, methylphenidate, psychostimulants, drug safety, long-term efficacy, sleep disorders, growth reduction, appetite loss, psychiatric adverse events, brain development
MeSH terms
Central Nervous System Stimulants, Animals, Attention Deficit Disorder with Hyperactivity, Brain, Humans, Methylphenidate, Time Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. https://app.cochat.ai/papers/10.1080/14740338.2017.1301928
The paper
Groenman, A. P., Schweren, L. J. S., Dietrich, A., & Hoekstra, P. J. (2017). An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2017.1301928

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.